A detailed history of State Of Wisconsin Investment Board transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, State Of Wisconsin Investment Board holds 100,982 shares of XENE stock, worth $3.87 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
100,982
Previous 89,800 12.45%
Holding current value
$3.87 Million
Previous $3.5 Million 13.48%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$36.12 - $43.96 $403,893 - $491,560
11,182 Added 12.45%
100,982 $3.97 Million
Q2 2024

Aug 14, 2024

SELL
$36.25 - $43.75 $71,956 - $86,843
-1,985 Reduced 2.16%
89,800 $3.5 Million
Q1 2024

May 14, 2024

SELL
$42.66 - $50.04 $151,485 - $177,692
-3,551 Reduced 3.72%
91,785 $3.95 Million
Q4 2023

Feb 12, 2024

SELL
$28.7 - $46.46 $21,180 - $34,287
-738 Reduced 0.77%
95,336 $4.39 Million
Q3 2023

Nov 14, 2023

SELL
$34.16 - $39.73 $3.96 Million - $4.61 Million
-116,055 Reduced 54.71%
96,074 $3.28 Million
Q2 2023

Aug 14, 2023

SELL
$34.84 - $43.54 $67,136 - $83,901
-1,927 Reduced 0.9%
212,129 $8.17 Million
Q1 2023

May 15, 2023

SELL
$33.46 - $40.35 $119,251 - $143,807
-3,564 Reduced 1.64%
214,056 $7.66 Million
Q4 2022

Feb 14, 2023

BUY
$33.06 - $39.43 $4,826 - $5,756
146 Added 0.07%
217,620 $8.58 Million
Q3 2022

Nov 14, 2022

BUY
$30.79 - $39.82 $5.29 Million - $6.84 Million
171,651 Added 374.6%
217,474 $7.85 Million
Q2 2022

Aug 15, 2022

BUY
$25.44 - $35.16 $295,689 - $408,664
11,623 Added 33.99%
45,823 $1.39 Million
Q1 2022

May 13, 2022

BUY
$25.09 - $33.13 $858,078 - $1.13 Million
34,200 New
34,200 $1.05 Million

Others Institutions Holding XENE

About Xenon Pharmaceuticals Inc.


  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.39B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track State Of Wisconsin Investment Board Portfolio

Follow State Of Wisconsin Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wisconsin Investment Board with notifications on news.